ストックスクリーナーアプリを入手
1.38
12.66%
-0.20
アフターアワーズ：
1.35
-0.03
-2.17%
Alx Oncology Holdings Inc (ALXO) 最新ニュース
ALXO Q1 2026 Earnings: EPS Beat Amid Pre‑Revenue Development StageEarnings Yield Analysis - newsline.com
ALX Oncology (ALXO) Edges Higher: Near-Term Support and Resistance in FocusLow Volume Node - newsline.com
ALXO Q1 2026 Earnings: EPS Surprise of 26.23% Highlights Cost Discipline Amid Clinical ProgressRevenue Recognition Risk - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares HigherEarnings Cycle Outlook - newsline.com
ALXO News | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Shareholders Approve Directors and Executive Pay - TipRanks
ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit - Stock Titan
ALX Oncology targets key readouts to advance CD47, EGFR cancer drug programs - MSN
ALXO: All voting proposals passed and clinical programs advanced, with key data expected soon - TradingView
ALX Oncology Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
ALXO Q1 2026 Earnings: EPS Beat Highlights Improved Cost Control in Pre-Revenue StageManagement Tone Analysis - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined Cost ManagementFinancial Health Score - newsline.com
ALX Oncology (ALXO) Q1 2026 Earnings Transcript - AOL.com
ALXO Q1 2026 Earnings: EPS Beat Driven by Lower Expenses, Stock Slightly DownProfit Cycle Analysis - newsline.com
Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15% - simplywall.st
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs - inkl
ALXO: Evorpacept and ALX2004 advance with strong data, robust funding, and pivotal trials planned - TradingView
ALXO: Evorpacept and ALX2004 advance with strong data, targeting high unmet needs and pivotal trials ahead - TradingView
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York - Investing News Network
Cancer-therapy biotech ALX Oncology to join Jefferies 2026 - Stock Titan
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Slips 1.5% as Biotech Stock Tests Key Support at $1.83Fibonacci Entry Signals - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Evorpacept DevelopmentEPS Revision Trend - The Legal Advocate
ALX Oncology Holdings (ALXO) Holds Steady Near Support as Biotech Sector Watches Catalyst CalendarTrend Reversal Picks - newsline.com
Is ALX Oncology Holdings (ALXO) outperforming other medical stocks this year? - MSN
ALX Oncology (ALXO) Edges Higher Amid Modest Buying Interest; Resistance at $2.06 in FocusMoney Flow Index - The Legal Advocate
ALX Oncology (ALXO) Lightstone group falls below 5% ownership - Stock Titan
ALXO Q1 2026 Earnings: Narrower-than-Expected Loss per Share Mirrors Clinical-Stage FocusEarnings Analysis - The Legal Advocate
ALXO Q1 2026 Earnings: EPS Beat Highlights Controlled Cash Burn, No Revenue YetDividend Cut Risk - Newser
Why Is ALX Oncology Holdings Inc. (ALXO) Stock Down Today? - Meyka
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
Redmile Group, ALXO: Investment manager discloses 6.8% ownership - Stock Titan
HBM Healthcare (ALXO) discloses 8.59M shares, ~6.5% stake - Stock Titan
Earnings call transcript: ALX Oncology beats Q1 2026 earnings forecast - Investing.com
Q2 EPS Estimates for ALX Oncology Raised by HC Wainwright - MarketBeat
TradingKey - TradingKey
UBS Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q1 2026 Earnings Call Transcript - Insider Monkey
Alx Oncology Signals Promise, But Validation Looms - TipRanks
ALX Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS - MSN
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Why ALX Oncology (ALXO) could deliver where others fall short (-0.53%) 2026-05-11Long Short Pair - newsline.com
ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Moomoo
ALX Oncology Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ALXO: ALX Oncology Reports Promising Data on CD47 Biomarker in H - GuruFocus
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
ALX ONCOLOGY ($ALXO) Releases Q1 2026 Earnings - Moomoo
ALX Oncology Holdings Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALXO) 2026-05-08 - Seeking Alpha
ALX Oncology Q1 Earnings Call Highlights - Barchart.com
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):